NasdaqGS:PGENBiotechs
A Look at Precigen’s (PGEN) Valuation After FDA Nod for Papzimeos and New Institutional Backing
Precigen (PGEN) shares climbed following two major developments: the FDA granted full approval for Papzimeos, the only authorized treatment for recurrent respiratory papillomatosis, and Patient Capital Management ramped up its investment in the company.
See our latest analysis for Precigen.
The FDA green light for Papzimeos and Patient Capital’s hefty investment gave Precigen’s story fresh momentum, driving a massive 112% share price return over the past 90 days and vaulting its 1-year total...